Rezgui Amel, Thabet Maissa, Makki Sahar, Anoun Jihed, Hassine Imen Ben, Karmeni Monia, Ben Fredj Fatma, Mzabi Anis, Laouani Chedia
Department of Internal Medicine, Sahloul Hospital, University of Sousse, Faculty of Medicine of Sousse, Tunisia.
Reumatologia. 2021;59(2):111-114. doi: 10.5114/reum.2021.103394. Epub 2021 Feb 9.
Coexistence of spondyloarthritis (SpA) and Takayasu's arteritis is not a common finding, but such cases have been discussed, particularly in the context of choice of therapy. Inhibition of inflammation by tumor necrosis factor inhibitors (TNFi) is a key aspect of the treatment of SpA and also positive effects of such treatment in concomitant large vessel vasculitis have been reported. However, TNFi is also associated with the possibility of initiating vasculitis. The present article based on a case study and the available literature is an attempt to discuss coexistence of these two diseases and the impact of treatment with biological drugs from the anti-TNF group in the course of SpA with Takayasu's arteritis.
脊柱关节炎（SpA）与大动脉炎并存并不常见，但已有相关病例讨论，尤其是在治疗选择方面。肿瘤坏死因子抑制剂（TNFi）抑制炎症是SpA治疗的关键环节，且有报道称此类治疗对合并的大血管血管炎也有积极作用。然而，TNFi也与引发血管炎的可能性相关。本文基于一个病例研究及现有文献，试图探讨这两种疾病的并存情况以及抗TNF类生物药物治疗在合并大动脉炎的SpA病程中的影响。
